Aurora Kinase B Market Trends And Growth Drivers Point To Strong Future Potential
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Aurora Kinase B Market Revenue Growth Supported By A CAGR Of 2.22% Through 2030
The aurora kinase b market has experienced rapid expansion in recent years, with projections indicating an increase from $1.27 billion in 2025 to $1.43 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.0%. This historical growth has been driven by progress in molecular oncology research, the recognition of aurora kinase b as a viable cancer target, the broadening of clinical trial capabilities, heightened funding directed at targeted cancer treatments, and advancements in the development of kinase inhibitors.
The aurora kinase b market is anticipated to experience significant expansion over the coming years. By 2030, its value is projected to reach $2.22 billion, reflecting a compound annual growth rate (CAGR) of 11.7%. This upcoming growth is driven by several key factors, including a rising need for precision cancer treatments, an increasing adoption of personalized medicine, a surge in oncology clinical trials, heightened funding for novel kinase inhibitors, and more favorable regulatory frameworks for targeted cancer drugs. Among the main developments shaping this forecast period are the accelerated creation of selective aurora kinase b inhibitors, a stronger focus on drug combinations in oncology, the broadening of precision oncology development pipelines, a heightened emphasis on therapies that target mitotic processes, and enhanced patient selection based on biomarkers.
Download A Free Sample Report For Comprehensive Market Insights:
Aurora Kinase B Market Growth Factors Supporting Long-Term Expansion
The projected expansion of the aurora kinase B market is anticipated to be driven by the growing prevalence of cancer. Cancer encompasses a range of disorders marked by the unregulated proliferation and dissemination of abnormal cells, which can invade adjacent tissues and spread to distant organs throughout the body. The uptick in cancer diagnoses is fueled by an aging demographic, shifts in lifestyle habits, environmental influences, and enhanced screening and diagnostic methods. Aurora kinase B is essential during mitosis, and its elevated expression is associated with genomic instability and the advancement of cancer. Because it plays a key role in tumor cell division, it is frequently pursued as a target in oncological treatments. As an example, in February 2024, data from the World Health Organization, an intergovernmental entity headquartered in Switzerland, revealed approximately 20 million new cancer diagnoses and 9.7 million fatalities in 2022. Projections suggest that by 2050, new cancer cases could surpass 35 million, marking a 77% rise compared to 2022. Consequently, the rising frequency of cancer is fueling the aurora kinase B market’s growth.
Aurora Kinase B Market Segment Breakdown: Which Categories Generate The Most Revenue?
The aurora kinase b market covered in this report is segmented –
1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types
2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications
3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811
2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies
3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib
4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies
5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials
6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology
Aurora Kinase B Market Industry Trends Shaping Future Revenue Growth
Key players in the aurora kinase B market are introducing advanced solutions, like aurora kinase inhibitors, with the aim of precisely interfering with essential cell division mechanisms. These inhibitors function by suppressing the activity of Aurora kinases, which play a vital role in mitosis, thus hindering cancer cell growth and possibly slowing tumor development. A notable example occurred in June 2023, when Ellipses Pharma, a biotechnology firm based in the UK, received approval from the U.S. Food and Drug Administration (FDA) for its candidate EP0042. This compound is a dual inhibitor that targets both FLT-3 and Aurora kinase. Developed to address acute myeloid leukemia (AML), EP0042 is particularly intended for patients whose disease has become resistant to FLT3 inhibitors alone. Studies indicate that by inhibiting both FLT3 and Aurora kinase, it is possible to overcome such acquired resistance, as shown in both laboratory experiments and animal models.
Aurora Kinase B Market Key Players And Strategic Industry Positioning
Major companies operating in the aurora kinase b market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc
Access The Complete Aurora Kinase B Market Report:
Aurora Kinase B Market Geographic Distribution And Regional Opportunities
North America was the largest region in the aurora kinase B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
